AENITIS TECHNOLOGIES

Their core work

Aenitis Technologies is a French medical technology SME developing acoustic-based blood cell sorting devices. Their core technology uses ultrasonic (acoustophoresis) waves to separate and purify blood components without centrifugation or chemical markers, targeting transfusion medicine, cell therapy preparation, and blood product processing. As a health-sector deep-tech startup, they work at the intersection of biomedical engineering, microfluidics, and clinical blood handling. Their value proposition is a gentler, label-free, automated alternative to conventional blood separation used in hospitals and cell therapy labs.

What they specialise in

How they've shifted over time

From 2016 to 2021 Aenitis followed the classic EU SME Instrument ladder: a small Phase 1 feasibility study in 2016 (EUR 50,000) validated the business case for their acoustic blood sorter, followed by a EUR 3.95M Phase 2 grant in 2018-2021 to bring the ABC-S device toward market readiness. Their focus did not diversify — it deepened on the same core product, moving from concept validation to prototype and clinical/industrial scale-up. There is no visible pivot; they are a single-technology company doubling down on acoustic blood sorting.

After 2021 they should be approaching market entry or early clinical adoption of the ABC-S device, making them interesting for partners in transfusion centers, cell therapy manufacturers, and hospital procurement networks.

How they like to work

Aenitis coordinated both of its H2020 grants solo under the SME Instrument, which is a single-beneficiary scheme — so the public H2020 record shows no consortium partners. This pattern is typical of a focused deep-tech SME that owns its IP and uses EU funding to develop its own product rather than to join shared research consortia. Partners engaging with them should expect a product-centric, IP-conscious company, not an academic consortium player.

No consortium partners are recorded because both projects were single-beneficiary SME Instrument grants. Their network in H2020 is effectively just themselves, operating from Mitry-Mory in the Paris region.

What sets them apart

Aenitis is one of very few European SMEs commercializing acoustophoresis specifically for blood component separation — a narrow, clinically relevant niche where most alternatives still rely on centrifuges or membrane filters. The EUR 3.95M Phase 2 grant suggests the EIC considered their technology among the stronger deep-tech health bets of its cohort. For a partner, the value is access to a proprietary, label-free, gentle cell-handling platform that could plug into transfusion, apheresis, or cell therapy workflows.

Highlights from their portfolio

• ABC-S (Phase 2, 2018-2021)
  Near EUR 4M SME Instrument Phase 2 grant — a strong EIC bet on bringing their acoustic blood sorter from prototype to market.
• ABC-S (Phase 1, 2016)
  The EUR 50,000 feasibility study that qualified them for Phase 2, showing a textbook successful SME Instrument progression.